{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:20:32Z","timestamp":1780143632230,"version":"3.54.0"},"reference-count":124,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Global cancer incidence reached 20 million new cases across 185 countries in 2022, with approximately 10 million cancer-related deaths annually. Among adults with solid tumors and hematological malignancies, infections are a major contributor to morbidity and mortality, with respiratory infections playing a particularly significant role. These infections not only reduce life expectancy but can also delay cancer therapy, negatively affect treatment outcomes, and increase healthcare costs. In recent years, the burden of respiratory infections in this population has been driven by influenza virus, SARS-CoV-2, respiratory syncytial virus, Streptococcus pneumoniae, and Bordetella pertussis. Effective vaccines are available for all these pathogens and are recommended for adults with cancer, yet vaccination uptake remains suboptimal despite their heightened vulnerability. This review provides practical guidance for healthcare professionals on vaccinating adults with cancer against respiratory infections, summarizing key information to help clinicians address vaccination-related complacency, confidence, and convenience. Evidence from studies in both the general population and cancer patients consistently shows that vaccination benefits outweigh potential risks, with adverse event rates comparable to those seen in individuals without cancer. Early vaccination is encouraged, as there is limited justification for delaying immunization even when immune responses may be reduced. Vaccine dosing aligns with recommendations for the general population, with important exceptions. Live attenuated vaccines should be avoided because of the risk of replication and disease in immunocompromised patients, and selected groups may require booster doses to achieve adequate protection. Notably, cancer immunotherapy does not appear to impair vaccine-induced immune responses.<\/jats:p>","DOI":"10.3390\/vaccines14010105","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:16:59Z","timestamp":1769159819000},"page":"105","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vaccination Against Respiratory Infections in Adults with Cancer: A Concise Guide for Clinicians"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-7282","authenticated-orcid":false,"given":"Kay Choong","family":"See","sequence":"first","affiliation":[{"name":"Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, Singapore 119228, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"GBD Cancer Collaborators (2025). The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: A systematic analysis for the Global Burden of Disease Study 2023. Lancet, 406, 1565\u20131586.","DOI":"10.2139\/ssrn.5533924"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13027-021-00413-z","article-title":"Infectious diseases as a cause of death among cancer patients: A trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database","volume":"16","author":"Elhadi","year":"2021","journal-title":"Infect. Agents Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/23744235.2019.1592217","article-title":"High mortality from viral pneumonia in patients with cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yang, P., Zheng, Y., Chen, J., Ma, H., Yu, K., Chen, Y., Yang, Y., and Wu, B. (2021). Immediate risk of non-cancer deaths after a cancer diagnosis. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08707-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40121-021-00433-7","article-title":"Fatal Infections Among Cancer Patients: A Population-Based Study in the United States","volume":"10","author":"Zheng","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: A multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9343(97)80004-6","article-title":"Community respiratory virus infections in immunocompromised patients with cancer","volume":"102","author":"Whimbey","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mourad, D.F., Radwan, S., Hamdy, R., Elkhashab, D.M., Kamel, M.M., Abdel-Moneim, A.S., and Kadry, D.Y. (2024). Identification of Lower Respiratory Tract Pathogens in Cancer Patients: Insights into Fatal Outcomes. Microorganisms, 12.","DOI":"10.3390\/microorganisms12081686"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"002071","DOI":"10.1099\/jmm.0.002071","article-title":"Clinical characteristics and outcomes of viral respiratory infections in allogeneic haematopoietic stem cell transplantation recipients: A single-centre experience","volume":"74","author":"Hamdi","year":"2025","journal-title":"J. Med. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of Adults with Cancer: ASCO Guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","article-title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"29","author":"Rieger","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ofab198","DOI":"10.1093\/ofid\/ofab198","article-title":"Influenza Vaccination Rates Among Patients with a History of Cancer: Analysis of the National Health Interview Survey","volume":"8","author":"Chang","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lo Moro, G., Golzio, F., Calabrese, S.C., Scaioli, G., Basile, A., Siliquini, R., and Bert, F. (2025). Strategies to Increase Vaccinations in Adult Cancer Patients: A Systematic Review. Vaccines, 13.","DOI":"10.3390\/vaccines13090964"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1007\/s00432-023-04984-9","article-title":"Preventive health care in blood cancer survivors: Results from the ABC study","volume":"149","author":"Baum","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101215","DOI":"10.1016\/j.esmoop.2023.101215","article-title":"Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM)","volume":"8","author":"Pedrazzoli","year":"2023","journal-title":"ESMO Open"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mohr, A., Kloos, M., Schulz, C., Pfeifer, M., Salzberger, B., Bauernfeind, S., Hitzenbichler, F., Plentz, A., Loew, T., and Koch, M. (2022). Low Adherence to Pneumococcal Vaccination in Lung Cancer Patients in a Tertiary Care University Hospital in Southern Germany. Vaccines, 10.","DOI":"10.3390\/vaccines10020311"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/cid\/ciaa090","article-title":"Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study","volume":"72","author":"Andersen","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110596","DOI":"10.1016\/j.isci.2024.110596","article-title":"Low booster uptake in cancer patients despite health benefits","volume":"27","author":"Figueiredo","year":"2024","journal-title":"iScience"},{"key":"ref_22","unstructured":"World Health Organization (2023, October 21). Report of the SAGE Working Group on Vaccine Hesitancy. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/sage\/2014\/october\/sage-working-group-revised-report-vaccine-hesitancy.pdf?sfvrsn=240a7c1c_4."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1007\/s00277-024-05869-8","article-title":"Vaccine challenges in CLL: A comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia","volume":"103","author":"Kontandreopoulou","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"See, K.C. (2022). Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews. Vaccines, 10.","DOI":"10.3390\/vaccines10050800"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.vaccine.2015.12.037","article-title":"Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial","volume":"34","author":"Jamshed","year":"2016","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/cid\/ciad458","article-title":"Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients","volume":"77","author":"Thomas","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lai, J.J., Lin, C., Ho, C.L., Chen, P.H., and Lee, C.H. (2019). Alternative-Dose versus Standard-Dose Trivalent Influenza Vaccines for Immunocompromised Patients: A Meta-Analysis of Randomised Control Trials. J. Clin. Med., 8.","DOI":"10.3390\/jcm8050590"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.bbmt.2015.12.003","article-title":"Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients","volume":"22","author":"Halasa","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2302099","article-title":"Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age","volume":"389","author":"Hsiao","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_31","first-page":"CD008983","article-title":"Influenza vaccines in immunosuppressed adults with cancer","volume":"2","author":"Bitterman","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/bmt.2017.24","article-title":"A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients","volume":"52","author":"Natori","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e13604","DOI":"10.1111\/eci.13604","article-title":"Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review","volume":"51","author":"Spagnolo","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2495","DOI":"10.1002\/rmv.2495","article-title":"Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"34","author":"Wang","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lopez-Olivo, M.A., Valerio, V., Karpes Matusevich, A.R., Brizio, M., Kwok, M., Geng, Y., Suarez-Almazor, M.E., and Colmegna, I. (2022). Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis. Vaccines, 10.","DOI":"10.3390\/vaccines10081195"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2539593","DOI":"10.1080\/21645515.2025.2539593","article-title":"Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors","volume":"21","author":"Luo","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Fabbri, A., Ruggeri, E.M., Virtuoso, A., Giannarelli, D., Raso, A., Chegai, F., Remotti, D., Signorelli, C., and Nelli, F. (2025). Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study. Cancers, 17.","DOI":"10.3390\/cancers17121948"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rabello, L.S., Silva, J.R., Azevedo, L.C., Souza, I., Torres, V.B., Rosolem, M.M., Lisboa, T., Soares, M., and Salluh, J.I. (2015). Clinical outcomes and microbiological characteristics of severe pneumonia in cancer patients: A prospective cohort study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120544"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/SHK.0b013e3182866d32","article-title":"Outcomes in critically ill cancer patients with septic shock of pulmonary origin","volume":"39","author":"Legrand","year":"2013","journal-title":"Shock"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e000968","DOI":"10.1136\/esmoopen-2020-000968","article-title":"Influenza in hospitalised patients with malignancy: A propensity score matching analysis","volume":"5","author":"Li","year":"2020","journal-title":"ESMO Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41564-019-0447-0","article-title":"Direct interactions with influenza promote bacterial adherence during respiratory infections","volume":"4","author":"Rowe","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_44","unstructured":"GBD Lower Respiratory Infections, and Antimicrobial Resistance Collaborators (Lancet Infect. Dis., 2025). Global burden of lower respiratory infections and aetiologies, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023, Lancet Infect. Dis., online first."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40121-018-0185-2","article-title":"Post-Obstructive Pneumonia in Patients with Cancer: A Review","volume":"7","author":"Rolston","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12931-025-03336-0","article-title":"Trends in influenza- and pneumonia-related mortality in lung cancer patients from 1999 to 2022: A retrospective CDC WONDER analysis","volume":"26","author":"Woods","year":"2025","journal-title":"Respir. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.lungcan.2008.03.015","article-title":"Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients","volume":"62","author":"Lee","year":"2008","journal-title":"Lung Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4103\/singaporemedj.SMJ-2022-050","article-title":"Acute management of pneumonia in adult patients","volume":"64","author":"See","year":"2023","journal-title":"Singapore Med. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4103\/singaporemedj.SMJ-2022-002","article-title":"Approach to acute respiratory failure for frontline clinicians","volume":"63","author":"See","year":"2022","journal-title":"Singapore Med. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1055\/s-0033-1343894","article-title":"Sepsis and thrombosis","volume":"39","author":"Levi","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1701794","DOI":"10.1183\/13993003.01794-2017","article-title":"Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: A self-controlled case series analysis of national linked datasets from Scotland","volume":"51","author":"Blackburn","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/CCM.0000000000002245","article-title":"Impact of Acute Kidney Injury in Patients Hospitalized with Pneumonia","volume":"45","author":"Chawla","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0002-9343(97)00003-X","article-title":"Respiratory viral infections in immunocompetent and immunocompromised persons","volume":"102","author":"Couch","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.21203","article-title":"Epidemiology and outcomes of serious influenza-related infections in the cancer population","volume":"104","author":"Cooksley","year":"2005","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17476348.2021.1842203","article-title":"Influenza and pneumonia-attributed deaths among cancer patients in the United States; a population-based study","volume":"15","year":"2021","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","article-title":"Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients with or Without Cancer","volume":"8","author":"Lei","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1182\/bloodadvances.2024015260","article-title":"Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: Focus on the very early period and Omicron era","volume":"9","author":"Hedberg","year":"2025","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/idr16020026","article-title":"Respiratory Syncytial Virus Infections in Recipients of Bone Marrow Transplants: A Systematic Review and Meta-Analysis","volume":"16","author":"Ricco","year":"2024","journal-title":"Infect. Dis. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"ofae513","DOI":"10.1093\/ofid\/ofae513","article-title":"Clinical Manifestations and Outcomes in Adults Hospitalized with Respiratory Syncytial Virus and Influenza a\/B: A Multicenter Observational Cohort Study","volume":"11","author":"Clausen","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"ofaf127","DOI":"10.1093\/ofid\/ofaf127","article-title":"Outcomes and Risk Factors for Influenza and Respiratory Syncytial Virus Lower Respiratory Tract Infections and Mortality in Patients with Lymphoma or Multiple Myeloma: A 7-Year Retrospective Cohort Study","volume":"12","author":"Shafat","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e70113","DOI":"10.1111\/tid.70113","article-title":"Respiratory Syncytial Virus Exceeded SARS-CoV-2 and Influenza in Lower Respiratory Infection and Mortality Rates Among Patients with Hematologic Malignancies During the 2023-2024 Respiratory Virus Season","volume":"27","author":"Shafat","year":"2025","journal-title":"Transpl. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"ofaf682","DOI":"10.1093\/ofid\/ofaf682","article-title":"Severity of Respiratory Syncytial Virus and Other Respiratory Viruses Versus Seasonal Influenza Among Hospitalized Patients with Cancer","volume":"12","author":"Wee","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103522","DOI":"10.1016\/j.eclinm.2025.103522","article-title":"Risk conditions for invasive pneumococcal disease in adults: A systematic review and meta-analysis","volume":"89","author":"Ditzel","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1017\/S0950268810000919","article-title":"Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies","volume":"138","author":"Wong","year":"2010","journal-title":"Epidemiol. Infect."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijid.2021.03.072","article-title":"Invasive pneumococcal disease among adults with hematological and solid organ malignancies: A population-based cohort study","volume":"106","author":"Knol","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"See, K.C. (2025). Pertussis Vaccination for Adults: An Updated Guide for Clinicians. Vaccines, 13.","DOI":"10.3390\/vaccines13010060"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bmt.1705495","article-title":"Bordetella pertussis respiratory infection following hematopoietic stem cell transplantation: Time for universal vaccination?","volume":"38","author":"Florax","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/107327481702400111","article-title":"Invasive Haemophilus influenzae Infection in Patients with Cancer","volume":"24","author":"Singh","year":"2017","journal-title":"Cancer Control"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","article-title":"Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review","volume":"226","author":"Chen","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_70","first-page":"CD015551","article-title":"Vaccines for preventing infections in adults with solid tumours","volume":"4","author":"Hirsch","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.vaccine.2021.12.046","article-title":"Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: Subgroup analysis of a global phase 3 randomized clinical trial","volume":"40","author":"Thomas","year":"2022","journal-title":"Vaccine"},{"key":"ref_72","first-page":"CD015530","article-title":"Vaccines for preventing infections in adults with haematological malignancies","volume":"5","author":"Zorger","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"See, K.C. (2023). Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making. Vaccines, 11.","DOI":"10.3390\/vaccines11050908"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102044","DOI":"10.1016\/j.eclinm.2023.102044","article-title":"Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): Final results of the multicentre, prospective, observational study","volume":"61","author":"Bersanelli","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/ijc.33340","article-title":"Association of postoperative influenza vaccine on overall mortality in patients undergoing curative surgery for solid tumors","volume":"148","author":"Gogenur","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e35574","DOI":"10.1002\/cncr.35574","article-title":"Influenza vaccine effectiveness in immunocompromised patients with cancer: A Danish nationwide register-based cohort study","volume":"131","author":"Amdisen","year":"2025","journal-title":"Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","article-title":"Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): A population-based test-negative case-control study","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1159\/000525962","article-title":"The Effect of Vaccination against COVID-19 in Cancer Patients: Final Results of the COICA Trial","volume":"100","author":"Ingenito","year":"2022","journal-title":"Oncology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.06.038","article-title":"COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study","volume":"175","author":"Lee","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2025.2020","article-title":"COVID-19 Vaccine Booster Uptake and Effectiveness Among US Adults with Cancer","volume":"11","author":"Skarbinski","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1038\/s41467-024-49285-y","article-title":"Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain","volume":"15","author":"Raventos","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.6004\/jnccn.2022.7048","article-title":"Immune-Related Adverse Events Among COVID-19-Vaccinated Patients with Cancer Receiving Immune Checkpoint Blockade","volume":"20","author":"Widman","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e019364","DOI":"10.1136\/bmjopen-2017-019364","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: A population-based propensity score matched cohort study","volume":"8","author":"Chiou","year":"2018","journal-title":"BMJ Open"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/cncr.33203","article-title":"Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study","volume":"127","author":"Li","year":"2021","journal-title":"Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"So, A.C.P., McGrath, H., Ting, J., Srikandarajah, K., Germanou, S., Moss, C., Russell, B., Monroy-Iglesias, M., Dolly, S., and Irshad, S. (2021). COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers, 13.","DOI":"10.3390\/cancers13143573"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2207438","DOI":"10.1080\/21645515.2023.2207438","article-title":"Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors","volume":"19","author":"Gilbert","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Javadinia, S.A., Alizadeh, K., Mojadadi, M.S., Nikbakht, F., Dashti, F., Joudi, M., Harati, H., Welsh, J.S., Farahmand, S.A., and Attarian, F. (2022). COVID-19 Vaccination in Patients with Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.860238"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmi.2025.09.013","article-title":"Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: An interventional cohort study","volume":"32","author":"Hall","year":"2026","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1016\/j.vaccine.2013.10.053","article-title":"Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours","volume":"31","author":"Wumkes","year":"2013","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cncr.30468","article-title":"Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles","volume":"123","author":"Keam","year":"2017","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4143\/crt.2019.189","article-title":"Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial","volume":"52","author":"Choi","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"552","DOI":"10.7326\/0003-4819-87-5-552","article-title":"Influenza immunization of adult patients with malignant diseases","volume":"87","author":"Ortbals","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ajh.27218","article-title":"Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL","volume":"99","author":"Campanella","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Acuti Martellucci, C., Rosso, A., Zauli, E., Bianconi, A., Fiore, M., Soldato, G., Marani Toro, P., De Benedictis, M., Di Marco, G., and Carota, R. (2025). The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and\/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study. Vaccines, 13.","DOI":"10.3390\/vaccines13030309"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Bai, S., Zhou, S., Zhang, J., Chen, W., Lv, M., Wang, J., Zhang, A., Wu, J., and Zhao, W. (2024). Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged \u226560 years: A phase 4, randomized, open-label study. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1437267"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2327736","DOI":"10.1080\/21645515.2024.2327736","article-title":"No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial","volume":"20","author":"Naficy","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1016\/j.vaccine.2023.10.050","article-title":"A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)","volume":"41","author":"Ramsay","year":"2023","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: A phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1016\/j.vaccine.2017.09.012","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults \u226550years of age: Results from a phase III, randomized, non-inferiority trial","volume":"35","author":"Drame","year":"2017","journal-title":"Vaccine"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Niyati, R., Rezahosseini, O., Ekenberg, C., Larsen, C.S., and Harboe, Z.B. (2025). Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review. Vaccines, 13.","DOI":"10.3390\/vaccines13060643"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"127293","DOI":"10.1016\/j.vaccine.2025.127293","article-title":"Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis","volume":"59","author":"Rahimi","year":"2025","journal-title":"Vaccine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1016\/j.vaccine.2016.10.020","article-title":"Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial","volume":"34","author":"Tashani","year":"2016","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/cid\/ciae365","article-title":"Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial","volume":"79","author":"Clark","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/infdis\/jiae342","article-title":"Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine","volume":"231","author":"Chime","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Chandler, R., Montenegro, N., Llorach, C., Aguirre, L.N., Germain, S., Kuriyakose, S.O., Lambert, A., Descamps, D., Olivier, A., and Hulstrom, V. (2024). Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered with a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial. Clin. Infect. Dis., ciad786.","DOI":"10.1093\/cid\/ciad786"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: An observer-blinded, placebo-controlled, randomised, phase 3 trial","volume":"25","author":"Goswami","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_108","first-page":"1774","article-title":"Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia","volume":"110","author":"Kattstrom","year":"2025","journal-title":"Haematologica"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.vaccine.2018.03.029","article-title":"Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA","volume":"36","author":"Pool","year":"2018","journal-title":"Vaccine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bmt.1703228","article-title":"Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines","volume":"28","author":"Nordoy","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e14109","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Silva-Pinto, A., Abreu, I., Martins, A., Bastos, J., Araujo, J., and Pinto, R. (2024). Vaccination After Haematopoietic Stem Cell Transplant: A Review of the Literature and Proposed Vaccination Protocol. Vaccines, 12.","DOI":"10.3390\/vaccines12121449"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-022-00299-6","article-title":"Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: A systematic review and meta-analysis","volume":"11","author":"Ge","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12985-024-02375-1","article-title":"Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: A systematic review and meta-analysis","volume":"21","author":"Azari","year":"2024","journal-title":"Virol. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/cid\/ciae291","article-title":"SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study","volume":"79","author":"Hill","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_116","first-page":"e146743","article-title":"Antibodies against vaccine-preventable infections after CAR T-cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"See, K.C. (2024). Enhancing COVID-19 Vaccination Awareness and Uptake in the Post-PHEIC Era: A Narrative Review of Physician-Level and System-Level Strategies. Vaccines, 12.","DOI":"10.3390\/vaccines12091038"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Shapiro Ben David, S., Shamai-Lubovitz, O., Mourad, V., Goren, I., Cohen Iunger, E., Alcalay, T., Irony, A., Greenfeld, S., Adler, L., and Cahan, A. (2023). A Nationwide Digital Multidisciplinary Intervention Aimed at Promoting Pneumococcal Vaccination in Immunocompromised Patients. Vaccines, 11.","DOI":"10.3390\/vaccines11081355"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3109\/10428194.2012.742524","article-title":"Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant","volume":"54","author":"Villa","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e4269","DOI":"10.1093\/cid\/ciaa1711","article-title":"A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation","volume":"73","author":"Teh","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2012.08.015","article-title":"A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation","volume":"19","author":"Karras","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_122","first-page":"CD006207","article-title":"Physical interventions to interrupt or reduce the spread of respiratory viruses","volume":"1","author":"Jefferson","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1002\/cncr.33598","article-title":"Cocooning against COVID-19: The argument for vaccinating caregivers of patients with cancer","volume":"127","author":"Woodfield","year":"2021","journal-title":"Cancer"},{"key":"ref_124","first-page":"3657","article-title":"Cocoon vaccination for influenza in patients with a solid tumor: A retrospective study","volume":"29","author":"Rensink","year":"2021","journal-title":"Support. Care Cancer"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T05:12:43Z","timestamp":1769404363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["vaccines14010105"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14010105","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}